Cargando…
VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy
BACKGROUND: Pathogenic gain of function variants in Valosin-containing protein (VCP) cause a unique disease characterized by inclusion body myopathy with early-onset Paget disease of bone and frontotemporal dementia (also known as Multisystem proteinopathy (MSP)). Previous studies in drosophila mode...
Autores principales: | Cheng, Cheng, Weiss, Lan, Leinonen, Henri, Shmara, Alyaa, Yin, Hong Z., Ton, Timothy, Do, Annie, Lee, Jonathan, Ta, Lac, Mohanty, Eshanee, Vargas, Jesse, Weiss, John, Palczewski, Krzysztof, Kimonis, Virginia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742393/ https://www.ncbi.nlm.nih.gov/pubmed/34998409 http://dx.doi.org/10.1186/s12967-021-03186-6 |
Ejemplares similares
-
A clinicopathologic study of malignancy in VCP-associated multisystem proteinopathy
por: Shmara, Alyaa, et al.
Publicado: (2022) -
Anti–Valosin‐Containing Protein (VCP/p97) Autoantibodies in Inclusion Body Myositis and Other Inflammatory Myopathies
por: Amlani, Adam, et al.
Publicado: (2022) -
Prevalence of Frontotemporal Dementia in Females of 5 Hispanic Families With R159H VCP Multisystem Proteinopathy
por: Shmara, Alyaa, et al.
Publicado: (2023) -
Provisional practice recommendation for the management of myopathy in VCP‐associated multisystem proteinopathy
por: Roy, Bhaskar, et al.
Publicado: (2023) -
Role of p97/VCP (Cdc48) in genome stability
por: Vaz, Bruno, et al.
Publicado: (2013)